Can a new combo help Graves' disease go into remission?
Part of Eyes & vision, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a combination of two medicines (methimazole and mycophenolate) to see if they can help people with newly diagnosed Graves' disease go into remission faster and more safely. If you are newly diagnosed and haven't had treatment yet, this study might offer a way to get better control of your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old
- You have just been diagnosed with Graves' disease (have not had treatment before)
- Your thyroid problems are not due to other causes (like lumps, nodules, or other thyroid diseases)
- You do not have severe eye problems from thyroid disease that need treatment
- Your liver, kidneys, heart, and blood counts are in a healthy range
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares different treatment plans to see how well they control Graves’ disease and whether it comes back. It may help by identifying which approach works best to prevent relapse.
This study tests efgartigimod, a new medicine given by injection under the skin, to see if it can help control Graves' disease (an overactive thyroid condition). The goal is to reduce the need for other thyroid medications or help people stop taking them.
This trial is testing a new drug, BHV-1300, to see if it works and is safe for people with Graves' disease. It might be an option if you have active hyperthyroidism (overactive thyroid) caused by Graves' disease and haven't had certain other treatments.
This study compares computer-guided dosing of methimazole (a common thyroid medication) to standard care for people with active Graves' disease. It tests whether digital support helps manage treatment better.
This trial tests an investigational drug called IMVT-1402 for people with Graves' disease whose thyroid is still overactive even while taking standard antithyroid medication. The goal is to see if the drug can better control thyroid hormone levels.
This early-phase trial tests a new type of treatment called CAR-T cells (special immune cells made in a lab) to target and calm down the overactive immune system in people with severe Graves' disease that hasn't improved with standard medicines. It may offer a new option for those who have been on treatment for years or have had multiple relapses.
Hear when a new Graves Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.